MYCOPHENOLATE MOFETIL-INDUCED VILLOUS ATROPHY

199887 citationsJournal Article

Authors

Didier Ducloux · Centre Hospitalier Universitaire de Besançon

Y Ottignon · Hôpital Saint-Julien

Sylvie Semhoun-Ducloux · Centre Hospitalier Universitaire de Nice

Sylvain Labb

Y Saint‐Hillier · Centre Hospitalier Universitaire de Rennes

Jean‐Philippe Miguet · Centre Hospitalier Universitaire de Nice

Pierre Carayon · Centre Hospitalier Universitaire de Nice

Abstract

Mycophenolate mofetil (MMF) is a new immunosuppressant developed for the prevention and treatment of acute renal rejection after transplantation. Diarrhea is the most frequent side effect observed during treatment with MMF. Its pathogenic mechanisms remain unknown. We describe a case of severe diarrhea due to villous atrophy in a renal transplant recipient during treatment with MMF. The patient was free of symptoms before MMF. Villous atrophy disappeared a few months after MMF withdrawal.

Topics & Keywords

Renal Transplantation Outcomes and Treatments Neurological Complications and Syndromes Pregnancy and Medication Impact

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Transplantation

Volume 66, Issue 8, pp. 1115-1116

DOI: 10.1097/00007890-199810270-00027

Field-Weighted Citation Impact: 2.70